OBJECTIVES: Several health-economics models have evaluated cost-effectiveness of HPV vaccination in Germany. These static models do not consider the dynamics of infection or the herd immunity effect of vaccination on vaccinees' contacts. The objective of this study is to assess the epidemiological and economic impact of a prophylactic quadrivalent human papillomavirus vaccine (HPV6/11/16/18) in Germany with the help of  a dynamic transmission model. METHODS: We adapted a previously published HPV6/11/16/18 dynamic transmission model to the German context. The model was populated with German-specific data where available and was manually calibrated to fit German epidemiological data. The base case analysis evaluated the current HPV vaccination programme for girls aged 12-17 years (cumulative coverage rate at 20 years of 45% and 55% for the 12-14 and 15-17 respectively), alongside current cervical cancer screening, versus screening only. RESULTS:  At a steady state, the model projected that the vaccination strategy could reduce the number of HPV 6/11/16/18-related cervical cancer, CIN2/3, CIN1 and genital wart cases among women by 64.6%, 64.3%, 58.9% and 69.9% respectively. In addition, girls' vaccination could indirectly lead to a decrease of 48.2% of genital warts cases in males. The incremental cost-effectiveness ratio (ICER) of the current vaccination programme was estimated at €5,525 per QALY and €10,205 per LYG. Excluding vaccine's protection against HPV6/11 would increase the ICER to €10,296/QALY. An increase in girls' vaccination coverage rates would lead to a substantial disease reduction. CONCLUSIONS: In Germany, the current quadrivalent HPV vaccination programme can be regarded as a cost-effective strategy. An increase in vaccination coverage rate could lead to a more effective programme. Further public health benefits could be expected on other HPV-related diseases such as vulvar, vaginal and anal precancerous lesions on which the quadrivalent vaccine has demonstrated high efficacy.